左卡尼汀联合螺内酯治疗老年慢性心力衰竭患者的临床效果

目的:观察左卡尼汀联合螺内酯治疗老年慢性心力衰竭患者的临床效果。方法:选取112例老年慢性心力衰竭患者作为研究对象,以随机数字表法将其分为研究组与对照组各56例。对照组采用螺内酯治疗,研究组在对照组基础上联合左卡尼汀治疗,比较两组临床疗效、治疗前后心功能指标水平和不良反应发生率。结果:研究组治疗总有效率为92.86%(52/56),高于对照组的76.79%(43/56),差异有统计学意义(P<0.05);治疗后,观察组左室射血分数大于对照组,左室舒张末期容积和左室收缩末期容积小于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:左卡尼汀联合螺内酯治疗老年慢性心力衰竭患者可提高治疗总有效率,降低心功能指标水平,效果优于单纯螺内酯治疗。

Clinical effects of Levocarnitine combined with Spironolactone in treatment of elderly patients with chronic heart failure

Objective:To investigate clinical effects of Levocarnitine combined with Spironolactone in treatment of elderly patients with chronic heart failure.Methods:112 elderly patients with chronic heart failure were selected as the research objects,and were divided into study group and control group by using the random number table method,each with 56 cases.The control group was treated with Spironolactone,while the study group was treated with Levocarnitine on the basis of that of the control group.The clinical efficacy,the cardiac function index levels before and after the treatment and the incidence of adverse reactions were compared between the two groups.Results:The effective rate of treatment in the study group was 92.86%(52/56),which was higher than 76.79%(43/56)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the left ventricular ejection fraction of the study group was greater than that of the control group;the left ventricular end-diastolic volume and left ventricular end-systolic volume were smaller than those of the control group;and the differences were statistically significant(P<0.05).However,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Levocarnitine combined with Spironolactone in the treatment of the elderly patients with chronic heart failure can improve the effective rate of treatment and reduce the levels of cardiac function indicators.Moreover,it is superior to single Spironolactone.